Lexicon Pharmaceuticals Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.01 Intrinsic Value $4.57median of 2 methodsbased on filings through 30 Jun 2026 Market Price $1.88Price as of 30 Sep 2026 Significantly undervaluedIntrinsic value is 143% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (+143%) Data confidence Sign in to view data confidence Market Cap $834.3M Enterprise Value $844.8M Shares Outstanding 419.4M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Lexicon Pharmaceuticals presents a high-risk, high-reward 'multi-shot' biotech thesis centered on its SGLT1/2 inhibitor sotagliflozin (marketed as INPEFA for heart failure and pipeline candidate ZYNQUISTA for Type 1 Diabetes) alongside partnered assets like LX9851 with Novo Nordisk. While the company's financial position has dramatically improved in early 2026—narrowing its Q1 net loss to $1.0 million due to $20.0 million in milestone payments and securing a $100 million loan facility with Hercules Capital—near-term commercial product sales remain modest ($1.1 million for INPEFA). The stock's outlook is highly dependent on binary regulatory and clinical catalysts over the next 12 months, notably the mid-2026 NDA resubmission of ZYNQUISTA and the Q1 2027 Phase 3 readout for SONATA-HCM. Given the balanced risk-reward profile and binary outcomes, a Hold rating is warranted until regulatory clarity is achieved. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$2.00 Mean target$3.86 High · most bullish analyst$6.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario In the bear case, the FDA issues another Complete Response Letter (CRL) or demands additional clinical trials for ZYNQUISTA due to safety concerns (e.g., diabetic ketoacidosis risks) in the STENO1 trial. Additionally, the SONATA-HCM trial experiences delays or fails to meet its primary endpoint of KCCQ Clinical Summary Score improvement. Without a partner, pilavapadin development stalls, and the company is forced to execute highly dilutive equity raises to fund operations as its cash runway depletes toward 2027. Base CaseCentral scenario In the base case, Lexicon successfully resubmits the NDA for ZYNQUISTA in mid-2026, leveraging safety data from the investigator-initiated STENO1 trial, leading to FDA approval by late 2026 or early 2027. Meanwhile, the SONATA-HCM Phase 3 trial completes enrollment in mid-2026, keeping it on track for a Q1 2027 topline readout. Novo Nordisk continues to advance LX9851, triggering a third $10 million milestone payment in late 2026. INPEFA sales grow modestly, and the company maintains a disciplined cash burn rate, preserving its runway into 2027. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |